why choose us

First received: July 10, 2023

Clinical Trial: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Relapsed/Refractory B-Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma

Brief Summary: This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL).The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.

Read more